DNA vaccine

Phase 2Vaccine

NNational Institute of Allergy and Infectious Diseases (NIAID)

DNA vaccine is one of 53 biologic programs targeting Oropharyngeal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oropharyngeal CarcinomaRecruiting

Triple-Negative Breast CancerRecruiting

Oropharyngeal CarcinomaPhase 2

Recruiting

Triple-Negative Breast CancerPhase 2

Recruiting

Competition

Competitive Landscape

96 competitors in Triple-Negative Breast Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

30 2

Keytruda

Merck & Co.

Phase 3

24 3

Abraxane

Bristol-Myers Squibb

Phase 3

20 4

Trodelvy

Gilead

Phase 3

14 5

Tecentriq

Roche

Phase 3

13 6

Halaven

Eisai

Phase 3

11 7

Paraplatin

AAvyxa

Phase 3

26 8

Gemzar

Johnson & Johnson

Phase 3

8 9

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Imfinzi

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Oropharyngeal Carcinoma

NCT05799144

Q4 2029

Phase 1/2Recruiting

Triple-Negative Breast Cancer

NCT06631092

Clinical

Trials by Indication[1]

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT01706458·18 enrolled

Chronic Hepatitis1 trial

Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B

Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 1·NCT00988767·10 enrolled

Triple-Negative Breast Cancer1 trial

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

Recruiting·NNEC Bio B.V·Phase 1/2·NCT06631092·12 enrolled

4 more indications

Neuroblastoma1 trial

DNA Vaccination Against Neuroblastoma

Unknown status·—·Phase 1·NCT04049864·12 enrolled

Head and Neck Cancer1 trial

Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT01493154·2 enrolled

Immune Response1 trial

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00801697·192 enrolled

Oropharyngeal Carcinoma1 trial

An Open-Label Phase II Clinical Trial Assessing the Safety, Feasibility, Efficacy and Immunological Correlates of Heterologous Prime-Boost With pBI-11 (IM) and TA-HPV (IM) Combined With Pembrolizumab as Treatment for Patients With Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Recruiting·MMichael K. Gibson·Phase 2·NCT05799144·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for DNA vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DNA vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DNA vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

DNA vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2029

Trials by Indication[1]

Influenza1 trial

Immunogenicity1 trial

Prostate Cancer1 trial

Chronic Hepatitis1 trial

Triple-Negative Breast Cancer1 trial

Neuroblastoma1 trial

Head and Neck Cancer1 trial

Immune Response1 trial

Oropharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News